LRMR
Price
$2.40
Change
-$0.01 (-0.41%)
Updated
Jun 4, 10:30 AM (EDT)
Capitalization
141.18M
64 days until earnings call
MDNAF
Price
$0.69
Change
-$0.01 (-1.43%)
Updated
Jun 3 closing price
Capitalization
53.56M
21 days until earnings call
Interact to see
Advertisement

LRMR vs MDNAF

Header iconLRMR vs MDNAF Comparison
Open Charts LRMR vs MDNAFBanner chart's image
Larimar Therapeutics
Price$2.40
Change-$0.01 (-0.41%)
Volume$4.82K
Capitalization141.18M
Medicenna Therapeutics
Price$0.69
Change-$0.01 (-1.43%)
Volume$12.51K
Capitalization53.56M
LRMR vs MDNAF Comparison Chart
Loading...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDNAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LRMR vs. MDNAF commentary
Jun 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LRMR is a Buy and MDNAF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 04, 2025
Stock price -- (LRMR: $2.41 vs. MDNAF: $0.69)
Brand notoriety: LRMR and MDNAF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LRMR: 91% vs. MDNAF: 27%
Market capitalization -- LRMR: $141.18M vs. MDNAF: $53.56M
LRMR [@Biotechnology] is valued at $141.18M. MDNAF’s [@Biotechnology] market capitalization is $53.56M. The market cap for tickers in the [@Biotechnology] industry ranges from $321.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LRMR’s FA Score shows that 1 FA rating(s) are green whileMDNAF’s FA Score has 0 green FA rating(s).

  • LRMR’s FA Score: 1 green, 4 red.
  • MDNAF’s FA Score: 0 green, 5 red.
According to our system of comparison, both LRMR and MDNAF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LRMR’s TA Score shows that 5 TA indicator(s) are bullish while MDNAF’s TA Score has 5 bullish TA indicator(s).

  • LRMR’s TA Score: 5 bullish, 5 bearish.
  • MDNAF’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both LRMR and MDNAF are a good buy in the short-term.

Price Growth

LRMR (@Biotechnology) experienced а +31.69% price change this week, while MDNAF (@Biotechnology) price change was -8.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.76%. For the same industry, the average monthly price growth was +2.77%, and the average quarterly price growth was +0.74%.

Reported Earning Dates

LRMR is expected to report earnings on Aug 07, 2025.

MDNAF is expected to report earnings on Aug 08, 2025.

Industries' Descriptions

@Biotechnology (+5.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LRMR($141M) has a higher market cap than MDNAF($53.6M). LRMR YTD gains are higher at: -37.726 vs. MDNAF (-39.904). MDNAF has higher annual earnings (EBITDA): -18.65M vs. LRMR (-105.02M). LRMR has more cash in the bank: 158M vs. MDNAF (30M). MDNAF has less debt than LRMR: MDNAF (174K) vs LRMR (4.87M). LRMR (0) and MDNAF (0) have equivalent revenues.
LRMRMDNAFLRMR / MDNAF
Capitalization141M53.6M263%
EBITDA-105.02M-18.65M563%
Gain YTD-37.726-39.90495%
P/E RatioN/AN/A-
Revenue00-
Total Cash158M30M527%
Total Debt4.87M174K2,797%
FUNDAMENTALS RATINGS
LRMR vs MDNAF: Fundamental Ratings
LRMR
MDNAF
OUTLOOK RATING
1..100
6852
VALUATION
overvalued / fair valued / undervalued
1..100
20
Undervalued
46
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
9465
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LRMR's Valuation (20) in the null industry is in the same range as MDNAF (46). This means that LRMR’s stock grew similarly to MDNAF’s over the last 12 months.

LRMR's Profit vs Risk Rating (100) in the null industry is in the same range as MDNAF (100). This means that LRMR’s stock grew similarly to MDNAF’s over the last 12 months.

MDNAF's SMR Rating (96) in the null industry is in the same range as LRMR (100). This means that MDNAF’s stock grew similarly to LRMR’s over the last 12 months.

MDNAF's Price Growth Rating (65) in the null industry is in the same range as LRMR (94). This means that MDNAF’s stock grew similarly to LRMR’s over the last 12 months.

MDNAF's P/E Growth Rating (100) in the null industry is in the same range as LRMR (100). This means that MDNAF’s stock grew similarly to LRMR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LRMRMDNAF
RSI
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
88%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 7 days ago
86%
Bullish Trend 15 days ago
85%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 6 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDNAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NTCT23.410.58
+2.54%
NetScout Systems
GIL46.58-0.08
-0.17%
Gildan Activewear
BYFC6.30-0.05
-0.79%
Broadway Financial Corp
NEXN11.37-0.28
-2.40%
Nexxen International Ltd
CME282.31-8.40
-2.89%
CME Group

LRMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, LRMR has been loosely correlated with ERAS. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if LRMR jumps, then ERAS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LRMR
1D Price
Change %
LRMR100%
+9.30%
ERAS - LRMR
53%
Loosely correlated
+1.40%
IMNM - LRMR
50%
Loosely correlated
+2.21%
ACLX - LRMR
49%
Loosely correlated
+5.18%
ATXS - LRMR
49%
Loosely correlated
+3.77%
COGT - LRMR
48%
Loosely correlated
+3.21%
More

MDNAF and

Correlation & Price change

A.I.dvisor tells us that MDNAF and LRMR have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MDNAF and LRMR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDNAF
1D Price
Change %
MDNAF100%
-1.89%
LRMR - MDNAF
25%
Poorly correlated
+9.30%
VIR - MDNAF
25%
Poorly correlated
+3.16%
STOK - MDNAF
23%
Poorly correlated
+9.99%
CGEM - MDNAF
23%
Poorly correlated
+2.40%
PTCT - MDNAF
22%
Poorly correlated
+3.81%
More